Lexaria Bioscience Corp. announced on March 18, 2025, positive pharmacokinetic (PK) results from Human Study #3 (GLP-1-H24-3). The study compared an oral version of DehydraTECH-processed Zepbound® (tirzepatide) to conventional injected Zepbound®.
The results showed that orally delivered DehydraTECH-tirzepatide reached roughly equal end-of-study blood-concentration levels as the injected drug. While injected Zepbound® typically peaked on Day 2 and declined, DehydraTECH-tirzepatide blood levels increased steadily and consistently, generally still rising on Day 8, the final day of the study.
These PK findings complement previously announced results from January 14, 2025, which demonstrated a 47% reduction in adverse events and a 54% reduction in gastrointestinal side effects for oral DehydraTECH-tirzepatide, along with comparable reductions in blood glucose and increases in blood insulin. This comprehensive data supports the potential for Lexaria's oral capsules as a viable alternative to injected tirzepatide.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.